Actelion hit with $547M judgment as insurgents rally

Just as Actelion's executive team was gearing up for a showdown on Thursday with a rebellious crew of insurgent shareholders, the company was hit with a big court judgment. A jury ruled that Asahi Kasei Pharma should get $547 million to settle its claims against Actelion in a licensing dispute that followed Actelion's $420 million buyout of CoTherix in 2007. Actelion says it may appeal. "The news is a clear negative for Actelion both sentiment-wise and fundamentally. Without the activist process we would struggle to keep the Buy rating," said Kepler Capital Markets analyst Tero Weckroth. Story

Suggested Articles

Pillar is bankrolling a new accelerator for budding biotechs. Petri aims to serve biotech startups at the “frontier of biology and engineering.”

One of the last major, late-stage attempt at stopping Alzheimer’s using a BACE inhibitor has ended up on the trash pile with so many others.

The oligosaccharide microbiome modulator was no better than placebo at reducing lactose intolerance symptoms.